Shots:

• A sub-analysis from the Oxford’ P-I/II COV001 & P-II/III COV002 trials for Vaxzevria (as single or two doses) in patients aged 18 to 55yrs.- demonstrated strong immune responses following 2nd dose interval @45wks. & following 3rd boosting dose. The Ab levels remain uplifted from baseline @1yr. following a single dose
• An extended interval b/w 1st & 2nd dose of Vaxzevria @45wks. resulted in 18 times increase in Ab response measured by 28 days after the 2nd dose.
• Additionally- third dose of Vaxzevria @6mos. resulted in 6 times increase in Abs levels & maintained T cell response and showed higher neutralizing activity against Alpha (B.1.1.7)- Beta (B.1.351) & Delta (B.1.617.2) variants

  | Ref: AstraZeneca | Image: AstraZeneca